Worldwide Antibody Drug Conjugates Industry to 2030 - Key Trends and Forecasts

News provided by

Oct 08, 2021, 07:00 ET

DUBLIN, Oct. 8, 2021 /PRNewswire/ -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current and future potential of ADCs being developed for the treatment of various indications. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade.

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers.

In fact, the FDA has approved 11 ADCs, namely ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), moxetumomab pasudotox (Lumoxiti), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), and loncastuximab tesirine-lpyl (ZynlontaT) till date. The success of these therapeutics can be attributed to their high tumor selectivity and cell-killing potential of monoclonal antibodies, while limiting off target toxicities. These advantages have made ADCs a new frontier of chemotherapy, thus, bringing about a paradigm shift in the treatment protocol of different types of cancer.

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first quarter of 2021. With approximately 80 ADCs being investigated in more than 250 clinical trials, the pharmaceutical industry is witnessing a dynamic shift from conventional technologies to newer and more robust approaches for the development of such complex biomolecules. In the past few years, several well-funded start-ups / small companies, offering advanced linker technologies, more potent warheads, and novel conjugation technologies, were established. Moreover, multiple licensing deals were inked in the past few years between various stakeholders, to advance the development of ADCs product pipeline. It is worth noting that companies are also evaluating their proprietary ADCs in combination with other effective therapeutic modalities, such as epigenetic modulator, immune checkpoint inhibitors, and monoclonal antibodies.

ADC-based combination therapies offer multifaceted advantages, such as reduced drug resistance, improved drug efficacy, shrinking tumor metastasis, and increased cancer survival rates. In addition, novel conjugated drug molecules, such as bicycle drug conjugate (Bicycle Therapeutics), extracellular drug conjugate (Centrose), peptide conjugate (Esperance Pharmaceuticals), phospholipid drug conjugate (Cellectar Biosciences), radionucleotide conjugate (Nordic Nanovector), and tunable drug conjugate (BlinkBio) have also been introduced. Driven by the substantial progress in the use of novel ADC-based combination therapies, the associated clinical results, and ongoing technological advancement, coupled to the marketing authorization of multiple ADCs, the ADC therapeutics market is anticipated to grow at a commendable rate in the mid to long-term.

Amongst other elements, the report includes:

A detailed review of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, phase III, phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).
Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
A list of key opinion leaders (KOLs) within this domain, featuring detailed 22 matrices to assess the relative experience of the individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).
An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.
An analysis of the recent collaborations (since 2014) focused on the development of ADCs. It includes partnerships inked by various stakeholders in this domain, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and other relevant agreements.
An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing ADCs.
An in-depth analysis of the various patents that have been filed / granted related to ADCs. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2016 and 2021, highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions, and leading recipient organizations.
An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.

Key Questions Answered

Who are the leading players engaged in the development of ADCs?
Which indications can be treated with ADCs?
Which partnership models are commonly adopted by stakeholders in this domain?
What are the investment trends in this industry?
Which are the most active clinical trial centers?
Who are the key opinion leaders that can help you drive your development efforts?
How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. COMPANY AND DRUG PROFILES

6. KEY THERAPEUTIC AREAS

7. KEY OPINION LEADERS

8. TARGET COMPETITIVENESS ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. FUNDING AND INVESTMENT ANALYSIS

11. PATENT ANALYSIS

12. ACADEMIC GRANTS

13. CLINICAL TRIAL ANALYSIS

14. KEY COMMMERCIALIZATION STRATEGIES

15. PROMOTIONAL ANALYSIS

16. COMBINATION THERAPIES

17. NOVEL CONJUGATION TECHNOLOGY PLATFORMS

18. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING

19. COST PRICE ANALYSIS

20. CASE STUDY: CONTRACT MANUFACTURING OF ADCs

21. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS

22. SWOT ANALYSIS

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS

24. EXECUTIVE INSIGHTS

25. CONCLUSION

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

3SBio
3W Partners
4BIO Capital
5AM Ventures
6 Dimensions Capital
AbbVie
ABL Bio
AbTis
Actinium Pharmaceuticals (ATNM)
Acuta Capital Partners
Adage Capital Management
Adagene
ADC Therapeutics
Adcendo
Advanced Proteome Therapeutics
Advantech
Agensys
Ajinomoto Bio-Pharma
Ally Bridge Group
Alphamab Oncology
Alta Partners
Alteogen
AltruBio
Ambrx
Amgen
Amgen Ventures
Angiex
Antikor Biopharma
Apricot Capital
Aravis
ARCH Venture Partners
Arix Bioscience
Arrowpoint Partners
Asana BioSciences
Astellas Pharma
AstraZeneca
Auven Therapeutics
Avacta
Avalon Ventures
AVICT Global
Avipep Therapeutics
AVROBIO
Bayer
Bayern Kapital
BDC Capital
Beam Therapeutics
BeiGene
BioAtla
BioGeneration Ventures (BGV)
BioMed Valley Discoveries
BioMedPartners
Biotest
BlackRock
BlinkBio
Boehringer Ingelheim
Boehringer Ingelheim Venture Fund
BOM Capital
Boxer Capital
Boyu Capital
Bregua
BrickBio
BrightGene Bio-Medical Technology
Bristol-Myers Squibb
btov Partners
BVF Partners
Byondis
Calculus Capital
California Institute for Regenerative Medicine (CIRM)
Cambridge Enterprise, University of Cambridge
Canaan Partners
Cancer Prevention and Research Institute of Texas (CPRIT)
Cancer Research Technology (CRT)
Cancer Research UK
Casdin Capital
Catalent
Catalent Biologics
CEL Healthcare
Celgene
Cellerant Therapeutics
Celltrion
Centre for the Commercialization of Antibodies and Biologics (CCAB)
Centrose
Changjinboya
Chengcheng Capital
Chiesi Ventures
Children's Hospital Los Angeles
China Life Private Equity Investment
China Venture Capital Fund (CVC)
CITIC Private Equity (CPE)
Clovis Oncology
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
Coparion
Cormorant Asset Management
Crescendo Biologics
CStone Pharmaceuticals
CTI Life Sciences Fund
CureMeta
CytomX Therapeutics
Daiichi Sankyo
Debiopharm
Decheng Capital
Deerfield Management
Diatheva
dievini Hopp BioTech
Efung Capital
EirGenix
Eli Lilly
EMD Serono
Esperance Pharmaceuticals
Essex Bio-Technology
Eurostars
Eventide
Everest Medicines
Exelixis
Farallon Capital
Femtogenix
Fidelity Investments
Five Prime Therapeutics
Florida Institute of Technology
Fonds de solidarite FTQ
Foresite Capital
Fortis Therapeutics
Fosun Pharma (formerly Shanghai Fosun Pharmaceutical)
Freenome
GamaMabs Pharma
Genentech
GeneQuantum Healthcare
General Insurance Corporation of India (GIC)
Genmab
Genor Biopharma
GIC
Gilde Healthcare
Gilead Sciences
GlaxoSmithKline
Global Bio-India
Glycotope
Glykos
Glythera
Goodwin Biotechnology
Greater Bay Area Fund
GT Biopharma
Guotai Venture Capital
Gustave Roussy
Hangzhou DAC Biotech
Harbour BioMed
HBM Healthcare Investments
HealthCap
Heidelberg Pharma
Hercules Capital
Heritage Provider Network
High-Tech Grunderfonds
Hillhouse Capital
Hisun Pharmaceuticals
Hofon Capital
Sichuan Hongbo Equity Investment Fund Management
HOPU Investments
Huadong Medicine
Huagai Capital
Hudson Bay Capital Management
Humanwell Healthcare
Iconic Therapeutics
Iksuda Therapeutics
ImmuneOncia Therapeutics
ImmunoBiochem
ImmunoGen
Immunome
Immunomedics (acquired by Gilead Sciences)
Innate Pharma
Innovate UK
Invenra
Invus
IONTAS
IP Group
iProgen Biotech
Janchor Partners
Janus Henderson Investors
Jazz Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals
JLABS
Johnson & Johnson Innovation
Johnson Matthey
JT New Century
JX Partners
K2 Investment
Kairos Therapeutics
King Star Capital
Kite Pharma
KLUS Pharma
Lake Bleu Capital
Laurion Capital Management
Legend Capital
LegoChem Biosciences
Levena Biopharma
LifeSci Venture Partners
Lilly Asia Ventures (LAV)
Lilly Ventures
Logos Capital
Loyal Valley Capital
Lumira Capital
MAB Discovery
MabSpace Biosciences
MabVax
MacroGenics
Magenta Therapeutics
Matrix Capital Management
Mayo Clinic
MediaPharma
MedImmune (acquired by AstraZeneca)
Meltwind
Memorial Sloan Kettering Cancer Center
Menarini
Merck
Merck KGaA
Mersana Therapeutics
Millennium Pharmaceuticals
MilliporeSigma
Minomic
Shanghai Miracogen
Mitsubishi Tanabe Pharma
Morphotek (Eisai)
MS Ventures
Multiple Myeloma Research Foundation (MMRF)
Myeloma Investment Fund
NanoValent Pharmaceuticals
National Cancer Institute (NCI)
National Research Council of Canada (NRC)
Navrogen
NBE-Therapeutics
Nerviano Medical Sciences
New Enterprise Associates
Nexthera Capital
Nordic Nanovector
Northeast Securities Prosperity Healthcare Fund
NovImmune
Novo Holdings
NovoCodex Biopharmaceuticals
o2h Ventures
OBI Pharma
OCCIDENT
OGD2 Pharma
Oncolinx
Oncomatryx Biopharma
OPKO Health
OrbiMed Advisors
Oriza Seed Venture Capital
Osage University Partners
Otsuka Pharmaceutical
Overland ADCT BioPharma
Oxford BioTherapeutics (OBT)
Oxford Finance
PAG
Pappas Capital
Perceptive Advisors
Pfizer
Pfizer Ventures
pH Pharma
PharmAbcine
PharmaMar
Philogen
PICC Capital Equity Investment
Pierre Fabre
PolyTherics
PPF Capital Partners Fund
Puma Biotechnology
Pureos Bioventures
Pyxis
Pyxis Oncology
Qiming Venture Partners
Quantum Leap
RA Capital Management
Rakuten
Rakuten Medical
Ramot
Recepta Biopharma
Redalpine
Redmile Group
Redwood BioScience
Regeneron Pharmaceuticals
RemeGen
The Research Council of Norway
Ridgeback Capital Investments
Roche
Roche Venture Fund
Rock Springs Capital
RTW Investments
Samsara BioCapital
Samsung Biologics
Sanofi
Sarah Cannon Research Institute
SBI Group
Schroder Adveq (acquired by Schroders)
Seagen
Sequoia Capital China
Seventure Partners
Shanghai Pharmaceuticals
Shengda Group
Shenogen Pharma
Siamab Therapeutics
Silicon Valley Bank
Sinopharm Capital
SK
Skyline Ventures
Sofinnova Ventures
Soleus Capital
SOPHiA GENETICS
Sorrento Therapeutics
SOTIO
Springworks
Starling Ventures
Start Codon
Stonebridge Capital
Surveyor Capital
Sutro Biopharma
Suvretta Capital Management
Suzhou Wuzhong Biomedicine Industrial Park Investment
SV Health Investors
Synaffix
SyndicateRoom
Syndivia
Synthon
T. Rowe Price Associates
Taikang Insurance Group
Takeda Oncology
Takeda Pharmaceutical
Takeda Ventures
Tekla Capital Management
Terra Magnum Capital Partners (TMCP)
TF Capital
The Column Group
The Scripps Research Institute
Third Rock Ventures
TOT BIOPHARM
TRIO Pharmaceuticals
Triphase Accelerator
TRITON FUNDS
Tubulis
UCB
University of Copenhagen
University of Wisconsin Carbone Cancer Center (UWCCC)
Vaccinex
VelosBio (acquired by Merck)
Venrock Healthcare Capital Partners
Vertex Ventures
VI Partners
Vida Ventures
Viking Global Investors
Vir Biotechnology
Visterra
Vivo Capital
Wellington Management
WILD Family Office
Wild Ventures
WS Investments
WuXi AppTec (formerly known as WuXi PharmaTech)
WuXi Biologics
WuXi Healthcare Ventures
WuXi STA
Xintela
Y-Biologics
York University
Ysios Capital
Yuanda China
Yuhan Corporation
Yunfeng Capital
Zhejiang Teruisi Pharmaceutical
Zhejiang University Future Capital
Zheshang Venture Capital
Zymeworks

For more information about this report visit https://www.researchandmarkets.com/r/390dpc

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets